Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment
of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in
Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18

Please see full Press Release here: Deciphera Pharmaceuticals Announces QINLOCK Included in NCCN Guidelines for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designati